Form 8-K Oruka Therapeutics, Inc. For: May 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Oruka Therapeutics expands license agreement to include IBD indication
June 1, 2026 4:05 PM EDTOruka Therapeutics Inc. (NASDAQ: ORKA) amended its IL-23 license agreement with Paragon Therapeutics Inc. on May 29, 2026, expanding the therapeutic field to include inflammatory bowel disease.
The amendment modifies the original license agreement dated December 17, 2024, broadening the definition of "Field" to encompass all therapeutic,... More
